Grande Ospedale Metropolitano Bianchi Melacrino Morelli — Clinical Trial Site

65 Registered trials

23 Currently recruiting

Organisation

Grande Ospedale Metropolitano Bianchi Melacrino Morelli

Location

Reggio Calabria, Italy

Identifier

ORG-100043831

Address

Viale Europa, 89133, Italy

Departments

1518: U.O.C di dermatologia
3004: U.O.C. Ematologia
Anestesia e Rianimazione
C.T.M.O. Centro Unico Regionale Trapianti di Cellule Staminali e Terapie Cellulari “A. Neri”-
CTMO
Department of Hemato-Oncology and Radiotherapy - Transplantation and Cellular Therapies Unit
Dipartimento Onco-Ematologico e Radioterapico
DIPARTIMENTO ONCO-EMATOLOGICO E RADIOTERAPICO - UOC EMATOLOGIA
Divisione di Ematologia
Ematologia
Hematology
Hematology and Stem Cell Transplant Unit
Hematology Division
Hematology Unit
IT10004: U.O Ematologia
IT30019:UO Ematologia
N/A
Onco-ematologico e radioterapico
Oncologia Medica
Oncologia Medica - Grande Ospedale Metropolitano’ Bianchi
Oncology and Hematology Department
OU Nephrology, Dialysis and Transplantation
Presidio Morelli - C.T.M.O.
U.O.C. di Ematologia
U.O.C. Ematologia
U.O.C. Nefrologia abilitata al Trapianto
UC Centro Trapianti Midollo Osseo (CTMO)
UO Ematologia
UOC Centro trapianti midollo osseo
UOC Ematologia
UOC Ematologia e C.T.M.O. Centro Unico Regionale Trapianti di Cellule Staminali e Terapie Cellulari
UOSD Oncoematologia Pediatrica

Clinical trials at this site (65)

Search interface

VEMURAFENIB PLUS RITUXIMAB AS A CHEMOTHERAPY-FREE ALTERNATIVE TO CLADRIBINE FOLLOWED BY MRD-GUIDED RITUXIMAB IN FRONT-LINE HAIRY CELL LEUKEM… Recruiting

2024-520119-41-00 Previously untreated patients with diagnosis of HCL 4 2023-01-15
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Acute Myeloid Leukemia 5 2022-12-06
The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting

2023-510515-19-00 Higher-risk-myelodysplastic syndromes 5 2020-11-27
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c… Recruiting

2023-505901-17-00 Acute Myeloid Leukemia (LMA) with FLT3 mutation 5 2020-04-24
Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c… Recruiting

2023-510516-39-00 Acute B-cell Lymphoblastic Leukemia with minimal residu 4 2019-10-30
A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn… Ended

2023-505394-32-00 chronic graft versus host disease 5 2025-02-06
STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE… Ended

2024-520121-36-00 The following categories of HCL patients needing anti-l 4 2025-01-28
ICC APL STUDY 02 Treatment study for children and adolescents with Acute Promyelocytic Leukemia Ended

2024-518669-83-00 acute promyelocytic leukemia (APL) in children and adol 4 2024-12-05
Comparison between rituximab plus zanubrutinib versus rituximab monotherapy in untreated splenic marginal zone lymphoma patients Ended

2023-503755-10-00 Splenic marginal zone lymphoma 5 2024-05-17
A Phase 3b Study of BMS-986346 in Lower-risk Myelodysplastic Syndrome Participants Ended

2023-504541-31-00 Myelodysplastic syndrome 5 2024-03-06
1L LUSPA VS ESA IN NTD LOW-RISK MDS PATIENTS Ended

2022-500430-29-00 Myelodysplastic Syndrome (MDS) 5 2023-10-11
A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended

2023-504867-18-00 Patients with Paroxysmal Nocturnal Hemoglobinuria 5 2022-12-05
A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended

2024-510800-35-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-06-17
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended

2024-516868-28-00 Ph+ Acute Lymphoblastic Leukemia 4 2021-05-04
A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended

2023-509120-17-00 Myelofibrosis 5 2021-04-12
A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac… Ended

2024-514467-26-00 Indolent Systemic Mastocytosis 4 2021-04-07
Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk… Ended

2023-507153-16-00 Higher-Risk Myelodysplastic Syndrome 5 2020-11-18
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
A phase-2 academic trial testing, in two parallel non-randomized cohorts, the combination of ruxolitinib (JAK1/2 inhibitor) with brentuximab… Ended

2024-520123-83-01 Patients with relapsed or refractory cHL that has not r 4 2020-02-11
A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety of Luspatercept in subjects who have participated in other L… Ended

2022-502498-40-00 myelodysplastic syndrome (MDS); beta (β)-thalassemia (T 5 2019-07-26
Safety and efficacy of BL-8040 with G-CSF compared to Placebo with G-CSF for the collection of peripheral blood stem cells for autologous tr… Ended

2024-511953-23-00 Hematopoietic Stem Cell mobilization autologous transpl 5 2019-05-17
A randomized trial that compares Carfilzomib - Lenalidomide - Dexamethasone (KRd) versus Lenalidomide - Dexamethasone (Rd) in new diagnosed … Ended

2024-513396-41-00 PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE > 5 2019-05-15